Mechanisms Controlling PD-L1 Expression in Cancer

Overview

Journal Mol Cell

Publisher Cell Press

Specialty Cell Biology

Date 2019 Nov 1

PMID 31668929

Citations 433

Authors

Jong-Ho Cha

Li-Chuan Chan

Chia-Wei Li

Jennifer L Hsu

Mien-Chie Hung

Affiliations

Soon will be listed here.

Abstract

The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene) receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; encoded by the CD274 gene), is a major co-inhibitory checkpoint signaling that controls T cell activities. Various types of cancers express high levels of PD-L1 and exploit PD-L1/PD-1 signaling to evade T cell immunity. Blocking the PD-L1/PD-1 pathway has consistently shown remarkable anti-tumor effects in patients with advanced cancers and is recognized as the gold standard for developing new immune checkpoint blockade (ICB) and combination therapies. However, the response rates of anti-PD-L1 have been limited in several solid tumors. Therefore, furthering our understanding of the regulatory mechanisms of PD-L1 can bring substantial benefits to patients with cancer by improving the efficacy of current PD-L1/PD-1 blockade or other ICBs. In this review, we provide current knowledge of PD-L1 regulatory mechanisms at the transcriptional, posttranscriptional, post-translational, and extracellular levels, and discuss the implications of these findings in cancer diagnosis and immunotherapy.

Citing Articles

A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8 T cell fitness in solid tumours.

Pretto S, Yu Q, Bourdely P, Trusso Cafarello S, Van Acker H, Verelst J Nat Metab. 2025; .

PMID: 40065102 DOI: 10.1038/s42255-025-01233-w.

Discovery and functional characterization of canine PD-L1-targeted antibodies for evaluating antitumor efficacy in a canine osteosarcoma xenograft model.

Song M, Cho J, Park H, Song Y, Kim K, Ahn J Sci Rep. 2025; 15(1):7574.

PMID: 40038403 PMC: 11880529. DOI: 10.1038/s41598-025-90770-1.

Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.

Park M, Choi J, Maharub Hossain Fahim M, Asevedo E, Nurkolis F, Ribeiro R Front Pharmacol. 2025; 16:1504618.

PMID: 40034825 PMC: 11872924. DOI: 10.3389/fphar.2025.1504618.

Enhanced thrombopoiesis supplies PD-L1 to circulating immune cells via the generation of PD-L1-expressing platelets in patients with lung cancer.

Lee S, Jeong S, Kim Y, Noh J, Rho K, Kim H J Immunother Cancer. 2025; 13(2).

PMID: 40010769 PMC: 11865743. DOI: 10.1136/jitc-2024-010193.

The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes.

Shi T, Zhang H, Chen Y Cell Biosci. 2025; 15(1):27.

PMID: 39987091 PMC: 11846233. DOI: 10.1186/s13578-025-01368-z.

References

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Sun C, Mezzadra R, Schumacher T . Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018; 48(3):434-452. PMC: 7116507. DOI: 10.1016/j.immuni.2018.03.014. View

Lim S, Li C, Xia W, Cha J, Chan L, Wu Y . Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016; 30(6):925-939. PMC: 5171205. DOI: 10.1016/j.ccell.2016.10.010. View

Marzec M, Zhang Q, Goradia A, Raghunath P, Liu X, Paessler M . Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008; 105(52):20852-7. PMC: 2634900. DOI: 10.1073/pnas.0810958105. View

Zhang N, Bevan M . CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011; 35(2):161-8. PMC: 3303224. DOI: 10.1016/j.immuni.2011.07.010. View

Yang Y, Li C, Chan L, Wei Y, Hsu J, Xia W . Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018; 28(8):862-864. PMC: 6082826. DOI: 10.1038/s41422-018-0060-4. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Twa D, Chan F, Ben-Neriah S, Woolcock B, Mottok A, Tan K . Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014; 123(13):2062-5. DOI: 10.1182/blood-2013-10-535443. View

Kourie H, Klastersky J . Side-effects of checkpoint inhibitor-based combination therapy. Curr Opin Oncol. 2016; 28(4):306-13. DOI: 10.1097/CCO.0000000000000295. View

10.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S . Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019; 216(4):982-1000. PMC: 6446862. DOI: 10.1084/jem.20180870. View

11.

Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499. PMC: 5931375. DOI: 10.1038/nature22396. View

12.

Schildberg F, Klein S, Freeman G, Sharpe A . Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016; 44(5):955-72. PMC: 4905708. DOI: 10.1016/j.immuni.2016.05.002. View

13.

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M, Hsu J . PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017; 23(14):3711-3720. PMC: 5511572. DOI: 10.1158/1078-0432.CCR-16-3215. View

14.

Zhang N, Zeng Y, Du W, Zhu J, Shen D, Liu Z . The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol. 2016; 49(4):1360-8. DOI: 10.3892/ijo.2016.3632. View

15.

DArrigo P, Russo M, Rea A, Tufano M, Guadagno E, De Caro M . A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. Oncotarget. 2017; 8(40):68291-68304. PMC: 5620257. DOI: 10.18632/oncotarget.19309. View

16.

Chan L, Li C, Xia W, Hsu J, Lee H, Cha J . IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019; 129(8):3324-3338. PMC: 6668668. DOI: 10.1172/JCI126022. View

17.

Chen L, Gibbons D, Goswami S, Cortez M, Ahn Y, Byers L . Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5:5241. PMC: 4212319. DOI: 10.1038/ncomms6241. View

18.

Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S . PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Mol Cell. 2019; 74(6):1215-1226.e4. PMC: 6737939. DOI: 10.1016/j.molcel.2019.04.005. View

19.

Zhang Y, Yang P, Wang X . Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol. 2013; 24(3):153-60. PMC: 3943699. DOI: 10.1016/j.tcb.2013.09.007. View

20.

Lin H, Wei S, Hurt E, Green M, Zhao L, Vatan L . Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018; 128(2):805-815. PMC: 5785251. DOI: 10.1172/JCI96113. View